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Interaction of cyclosporine and FK506 with diuretics in trans- nesium wasting in animal models [3] and humans [4, 5].
plant patients. The mechanism of the effect of calcineurin inhibitors on
Background. The calcineurin inhibitors cyclosporine and magnesium wasting is not clear. Unlike other ions thatFK506 are widely used for immunosuppression in solid organ
are primarily reabsorbed in the proximal tubule, thetransplantation. One of the side effects of these agents is renal
majority of magnesium reabsorption occurs more dis-magnesium wasting. The site of action and molecular mecha-
nism of this effect are not known. We hypothesized that agents tally. Approximately 60% of filtered magnesium is reab-
such as diuretics that cause renal magnesium wasting through sorbed in the loop of Henle and another 5% in the distal
a similar action would not have an additive effect on magnesium
tubule [6]. The relatively small amount of magnesiumdeficiency with calcineurin inhibitors.
reabsorbed in the distal tubule accounts for 60% of theMethods. The records of 50 heart transplant patients on
calcineurin inhibitors were reviewed to determine levels of amount delivered to this segment and is thus physiologi-
serum magnesium and required replacement dose of magne- cally important in the regulation of magnesium homeo-
sium, diuretic usage, and other laboratory values. stasis. Since the thick limb of the loop of Henle provides
Results. Loop diuretics did not change either the magnesium
a large fraction of renal magnesium reabsorption andlevel or magnesium replacement requirements in patients on
the distal tubule plays an important part in the finalcalcineurin inhibitors. In contrast, the thiazide diuretic resulted
in an increase in serum magnesium and a decrease in magne- regulation of magnesium excretion, one of these seg-
sium replacement. Results were similar when the cyclosporine ments is likely to be the portion of the tubule in which
or FK506 groups were evaluated alone. Patients taking FK506 cyclosporine and FK506 work to inhibit renal magnesiumhad lower serum magnesium values and higher requirements
reabsorption. Interactions between diuretics, which actfor magnesium replacement compared with patients taking
cyclosporine. in specific portions of the tubule, and calcineurin inhibi-
Conclusion. We conclude that calcineurin inhibitors and tors could help to sort out the tubular sight of action of
loop diuretics have a similar site of action. these drugs. Loop diuretics, like furosemide and bumeta-
nide, are known to work in the thick ascending limb of
the loop of Henle [7] and are associated with magnesium
Cyclosporine and FK506 are commonly used to pre- loss [8]. Thiazide diuretics exert their actions in the distal
vent rejection after organ transplantation. Both inhibit convoluted tubule [9]. They have also been associated
the phosphatase calcineurin, although through different with Mg wasting with prolonged treatment, although the
mechanisms. Cyclosporine binds cyclophilin and FK506 direct effects of thiazides on the tubule are controversial
binds to FK-binding protein. These complexes inhibit
[10–12]. We reviewed the charts of 50 heart transplant
the Ca21- and calmodulin-dependent serine/threonine
patients to determine what interactions occurred be-
phosphatase calcineurin [1]. In T lymphocytes, calci-
tween cyclosporine or FK506 and diuretics on serumneurin is a key rate-limiting step in the activation of
magnesium levels and the required magnesium dose.transcription factors important for the expression of in-
terleukin-2 (IL-2) [2]. Both calcineurin inhibitors have
been associated with hypomagnesemia and urinary mag- METHODS
We reviewed the records of patients who had received
a heart transplant at Jewish Hospital in Louisville, Ken-Key words: magnesium deficiency, immunosuppression, heart trans-
plant, loop diuretics, calcineurin inhibition, thiazide diuretic. tucky, USA, between July 1, 1986, and November 30,
1998. Transplant coordinators kept flow sheets with labo-Received for publication October 25, 1999
ratory values and medicines for each patient. We ob-and in revised form January 5, 2000
Accepted for publication January 18, 2000 tained every measurement of magnesium from these flow
charts for 50 patients. The total number of magnesiumÓ 2000 by the International Society of Nephrology
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Table 1. Characteristics of heart transplant patients on calcineurin inhibitors
Cyclosporine FK506
level level
Number of Mean time since Median time since Male
measurements Age transplant days transplant days % DiabeticmEq/L
Cyclosporine 1755 48.860.3 859624 433 79 21462.9 66%
FK506 726 49.860.4a 786631 511 66 10.260.2 70%
aP , 0.05 compared to cyclosporine
that were slightly below the reference range (1.4 to 1.9
mEq/L) and significantly less than the cyclosporine group
(FK 1.39 6 0.01, CsA 1.55 6 0.006, P , 0.001). The
FK506 group also required a higher replacement dose
of magnesium (P , 0.001). Mean serum creatinine ex-
ceeded reference values in both groups but was signifi-
cantly higher in the FK506 group (1.67 6 0.02 mg/dL)
compared with cyclosporine (1.53 6 0.02, P , 0.001;
data not shown). The relationship between cyclosporine
or FK506 levels and serum magnesium or magnesium
Fig. 1. Serum magnesium level and dose of magnesium in patients on dose was analyzed by linear regression. No statistically
calcineurin inhibitors. Patients on FK506 had significantly lower serum significant correlation between drug level and hypomag-
magnesium and were on a higher dose of magnesium oxide compared
nesemia was found.with patients on cyclosporine (*P , 0.01). Symbols are: ( ) cyclos-
porine; (j) FK506. We evaluated the effect of diuretics on serum magne-
sium level and required magnesium dose for patients on
either calcineurin inhibitor (Table 2). Our primary goal
was to determine the effect of loop and thiazide diuretics
measurements was 2496. Where available, the following on serum magnesium levels and required magnesium
information was obtained for each date of magnesium
oxide dose. Mean values were determined for serum
measurement: serum creatinine, potassium, cyclospor-
magnesium levels obtained from patients on each class
ine, and FK506 levels. Doses of magnesium oxide, cy-
or combination of classes of diuretics. Data were not
closporine, FK506, and diuretics, and whether the patient
analyzed for the potassium-sparing diuretics (N 5 3) andwas diabetic were also recorded. Diabetes was defined
loop plus potassium-sparing diuretic (N 5 23) groupsas currently taking either insulin or a hypoglycemic
because of the small numbers in these groups. There wasagent. The age of patient and the length of time since
no difference in magnesium or magnesium dose betweentransplantation were calculated for each measurement.
patients not on diuretics and those on loop diuretics (Fig.Values are reported as mean and SEM. Comparisons
2). This demonstrates that loop diuretics do not producebetween groups were made using one-way analysis of
an additional magnesuric effect for patients already onvariance followed by Dunnett’s test.
calcineurin inhibitors. In contrast, patients on thiazide
diuretics had higher serum magnesium levels (control
RESULTS 1.47 6 0.01, thiazide 1.54 6 0.02 mEq/L, P , 0.05) and
lower required doses of magnesium (1186 6 38 vs. 643 6The charts of 50 heart transplant patients on either
98 mg magnesium oxide/day, P , 0.05) compared withcyclosporine or FK506 were reviewed. Characteristics of
patients who were not on diuretics. Patients on loop pluspatients on cyclosporine and FK506 are shown in Table 1.
thiazide diuretics had a higher serum magnesium levelPatients on cyclosporine were slightly younger (P , 0.05),
but no difference in the magnesium dose, while patientsand there was a trend toward a longer mean time since
on thiazide plus potassium-sparing diuretics had highertransplant, although the median time since transplant
magnesium levels and a lower magnesium dose than thewas longer in the FK506 group. The discrepancy between
control subjects.mean and median reflects the fact that three individuals
We next examined the results of the subgroup of pa-in this study had been transplanted for longer than 10
tients on cyclosporine. When the serum magnesium lev-years and all were on cyclosporine. Both groups had
els and magnesium requirement for patients on cyclo-more males than females and a similar proportion of
sporine were evaluated, the results were similar to thosediabetic patients. A comparison of magnesium values
seen in the entire group of patients on calcineurin inhibi-and magnesium dose between the two groups is seen in
Figure 1. Patients on FK506 had serum magnesium levels tors (Table 3). Loop diuretics had no effect on the serum
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Table 2. Effect of diuretics in heart transplant patients on calcineurin inhibitors
Loop plus Thiazide plus Loop plus thiazide plus
Control Loop Thiazide thiazide potassium-sparing potassium-sparing
Magnesium mEq/L
Mean 1.47 1.49 1.54a 1.76a 1.75a 1.58
N 862 1315 87 91 66 35
SEM 0.01 0.01 0.02 0.03 0.03 0.04
Potassium mEq/L
Mean 4.17 4.11 4.07 3.78a 3.83a 4.05
N 858 1284 87 90 65 35
SEM 0.02 0.01 0.05 0.05 0.05 0.09
Magnesium dose mEq/L
Mean 1186 1102 643a 1156 848a 2206
N 861 1309 87 91 66 35
SEM 38 29 98 124 101 155
aP , 0.05 compared to control
than the controls (1.41 6 0.02 vs. 1.72 6 0.1 mEq/L,
P , 0.05). There was a trend toward a higher dose of
magnesium in the loop plus thiazide group, but it did
not reach statistical significance.
DISCUSSION
Calcineurin inhibitors have previously been shown to
cause urinary magnesium wasting, but the renal site of
action of these agents has not been known. We hypothe-
sized that the addition of other promagnesuric agentsFig. 2. Comparison of serum magnesium level and dose of magnesium
for patients on calcineurin inhibitors. Patients on either cyclosporine working at the same renal tubular site or through a simi-
or FK506 were included in the analysis. Patients on loop diuretics did lar mechanism would not produce a further increase innot differ from those on no diuretics. Patients on thiazide diuretics had
magnesium loss beyond that seen with the calcineurina significantly higher serum magnesium concentration and were on a
lower dose of magnesium replacement than those on no diuretics (*P , inhibitors alone. Loop diuretics produce renal magne-
0.05). Symbols are: (j) control; ( ) loop diuretic; ( ) thiazide diuretic;
sium wasting, have a well-characterized site and mecha-( ) loop and thiazide diuretics; ( ) thiazide and potassium-sparing
diuretics; ( ) loop, thiazide and potassium-sparing diuretics. nism of action, and are commonly given to transplant
patients in combination with calcineurin inhibitors. Thia-
zide diuretics also have a well-characterized site and
mechanism of action for inhibition of sodium reabsorp-
magnesium level or magnesium dose, although there was
tion, but their effect on magnesium reabsorption is lessa significant decrease in serum potassium. The thiazide
clear. We have examined surrogates for magnesiumgroup had a significantly decreased magnesium require-
wasting in heart transplant patients on combinations ofment, although there was no difference in serum magne-
calcineurin inhibitors and diuretics.sium levels. Results for the groups taking combinations
We have attempted to determine interaction of diuret-of diuretics were essentially the same as for the analysis
ics with calcineurin inhibitors to produce renal magne-of calcineurin inhibitors as a whole.
sium wasting and magnesium deficiency. Since only aAmong patients on FK506, there were only three
small fraction of total magnesium is in the serum, thegroups based on diuretics. These groups were those on no
serum magnesium level is not necessarily reflective ofdiuretic, loop diuretics, and loop plus thiazide diuretics.
magnesium deficiency. A number of methods have beenThere were no patients on thiazide diuretics alone among
used to try to assess more accurately magnesium defi-the patients on FK506. The results in this group were
ciency, including skeletal muscle magnesium, red bloodsimilar to those seen for the calcineurin inhibitor group
cell (RBC) magnesium, platelet magnesium, and urinaryas a whole (Table 4). As in the cyclosporine group and
magnesium excretion in response to magnesium loadingthe total calcineurin inhibitor group, patients on loop
[13]. In this retrospective study, we have used the serumdiuretics did not differ from the patients on no diuretics
magnesium level and required magnesium dose to assessin terms of serum magnesium or dose of magnesium
magnesium loss. In combination, these two factors giveamong patients on FK506. Patients on loop plus thiazide
diuretics had a higher serum magnesium concentration a relatively good indication of the amount of magnesium
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Table 3. Effect of diuretics in heart transplant patients on cyclosporine
Loop plus Thiazide plus Loop plus thiazide plus
Control Loop Thiazide thiazide potassium-sparing potassium-sparing
Magnesium mEq/L
Mean 1.51 1.54 1.54 1.77a 1.76a 1.58
N 545 916 87 80 66 35
SEM 0.01 0.01 0.02 0.04 0.03 0.04
Potassium mEq/L
Mean 4.18 4.09a 4.07 3.79a 3.85a 4.05
N 541 909 87 80 65 35
SEM 0.02 0.02 0.05 0.05 0.05 0.09
Magnesium dose mEq/L
Mean 1110 970 644a 1020 848 2206a
N 545 916 87 80 66 35
SEM 44 32 98 118 101 155
aP , 0.05 compared to control
Table 4. Effect of diuretics in heart transplant patients on FK506 lumen. This pathway requires the apical surface Na1/
K1/2 Cl2 cotransporter and ROMK potassium channelsLoop plus
Control Loop thiazide [14] and Na1,K1-ATPase and CLCNKB Cl2 channels
Magnesium mEq/L [15, 16] on the basal surface (Fig. 3).
Mean 1.41 1.38 1.72a The mechanism of the renal magnesium wasting
N 317 398 11
caused by cyclosporine and FK506 is unclear. BothSEM 0.02 0.02 0.1
Potassium mEq/L agents inhibit Na1,K1-ATPase activity in the medullary
Mean 4.17 4.16 3.78 thick ascending limb and cortical collecting duct [17, 18].
N 317 374 10
Two other inhibitors of calcineurin, pentafluorophenolSEM 0.03 0.03 0.2
Magnesium dose mEq/L and peptide 412, also inhibited Na1,K1-ATPase activity.
Mean 1312 1416 2145 Rapamycin, which binds to the same immunophilin as
N 317 398 11
FK506 without inhibiting calcineurin, and SDZ 220-384,SEM 69 59 468
which binds to cyclophilin without inhibiting calcineurin,aP , 0.05 compared with control
do not inhibit Na1,K1-ATPase activity [18]. Phosphory-
lation of Na1,K1-ATPase by protein kinase C results in
inhibition of its activity [19]. Therefore, inhibition of
calcineurin may result in increased phosphorylation andlosses, which presumably occurs primarily through the
urine. decreased activity of Na1,K1-ATPase in the thick as-
cending limb. In the thick ascending limb, decreasedIn the current study, patients on FK506 had a greater
degree of magnesium wasting, as demonstrated by lower Na1,K1-ATPase activity would result in a decrease in
the lumen positive gradient, which is the driving forceserum magnesium and higher daily dose of oral magne-
sium compared with patients on cyclosporine. Among for magnesium reabsorption. This potential mechanism
for calcineurin inhibitors to decrease magnesium reab-all of the patients on calcineurin inhibitors, neither the
serum magnesium level nor required dose of magnesium sorption is outlined in Figure 3.
Loop diuretics bind to the chloride-binding sight ofwas different for patients on loop diuretics compared
with those who were not on diuretics. In contrast, pa- the Na1/K1/2 Cl2 cotransporter (NKCC) on the apical
surface of the thick ascending limb and inhibit its func-tients on thiazide diuretics had higher serum magnesium
levels and lower requirements for magnesium replace- tion. Inhibition of this transporter results in a loss of the
ability to produce the lumen-positive gradient that isment. Potassium was in the normal range and was not
significantly different between groups. The data for mag- the driving force for magnesium reabsorption. If loop
diuretics and calcineurin inhibitors work through thenesium were essentially the same when the cyclosporine
or FK506 groups were examined alone. same general mechanism to inhibit magnesium reabsorp-
tion, we would expect that the effects of these agentsMagnesium reabsorption in the renal tubule occurs by
distinct mechanisms in different tubular segments. In would not be additive. This is, in fact, what we have
seen in our study. Loop diuretics did not cause a furtherthe thick ascending limb, where the bulk of magnesium
reabsorption occurs, much of the reabsorption occurs decrease in serum magnesium or an increase in magne-
sium requirement compared with calcineurin inhibitorsthrough a paracellular pathway, and is driven by the
electrical lumen-positive gradient generated during reab- alone. This supports the hypothesis that calcineurin in-
hibitors increase urine magnesium loss through an effectsorption of NaCl with leak of K1 back into the tubular
Arthur and Shamim: Magnesium in transplant patients 329
and potassium depletion inhibits uptake [20]. The heart
transplant patients in this study were very closely followed
by a team of transplant coordinators and had frequent
laboratory assessment. In spite of the diuretic use, hypo-
kalemia was rare. Because of the close follow-up and
replacement of potassium and the tendency of calcineurin
inhibitors to increase potassium, hypokalemia was elimi-
nated as a potential cause of magnesium wasting. This
likely accounts for an unmasking of the beneficial effect
of thiazide diuretics on magnesium metabolism.
We have demonstrated that loop diuretics do not exac-
erbate the hypomagnesemic effects of calcineurin inhibi-
tors and that thiazide diuretics may ameliorate these
effects. When feasible, thiazide diuretics may be a better
choice for treatment of volume excess in patients on
calcineurin inhibitors in order to improve hypomagnese-
mia and to decrease the requirement for magnesium
supplementation.
Fig. 3. Schematic representation of thick ascending limb transport
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